奇正藏药(002287) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥152,316,037.10, a decrease of 39.97% compared to ¥253,751,327.31 in the same period last year[11] - The net profit attributable to shareholders for Q1 2020 was ¥48,730,150.83, down 42.52% from ¥84,775,457.81 in the previous year[11] - The basic earnings per share for Q1 2020 was ¥0.0924, a decrease of 42.54% compared to ¥0.1608 in the previous year[11] - The company's operating revenue decreased by 39.97% to ¥152,316,037.10 due to the impact of the pandemic[25] - Net profit attributable to the parent company fell by 42.52% to ¥48,730,150.83, reflecting a decline in operating income[28] - The company's operating profit for the current period is approximately ¥59.33 million, a decrease of 38% compared to ¥95.86 million in the previous period[67] - The total profit for the current period is approximately ¥54.15 million, down from ¥95.85 million, reflecting a decline of 43%[67] - The net profit attributable to the parent company's shareholders is approximately ¥48.73 million, a decrease of 42% from ¥84.78 million in the previous period[67] - The total comprehensive income attributable to the parent company's shareholders is approximately ¥49.28 million, down from ¥84.78 million, a decrease of 42%[70] - The company's revenue for the current period is approximately ¥90.46 million, a decrease of 33% from ¥134.99 million in the previous period[71] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥318,812,974.85, a 515.91% increase from -¥76,654,708.01 in the same period last year[11] - The net increase in cash and cash equivalents decreased by 93.26% to -¥475,078,652.65, primarily due to reduced cash flow from investment activities[28] - Cash and cash equivalents as of March 31, 2020, were ¥602,969,520.64, down from ¥901,265,437.89 at the end of 2019, indicating a liquidity contraction[54] - The ending balance of cash and cash equivalents was 871,672,211.69, down from 1,346,750,864.34 at the beginning of the period[84] - The company reported a net cash inflow from other operating activities of approximately ¥8.47 million, compared to ¥1.74 million in the previous period[78] - The net cash flow from operating activities was 318,812,974.85, a significant improvement compared to -76,654,708.01 in the previous period[81] - Cash inflow from investment activities totaled 32,460,000.00, down from 143,566,945.31 in the previous period[85] - The net cash flow from investment activities was -895,667,925.05, compared to -169,646,667.64 in the previous period, indicating increased investment outflows[81] - The net increase in cash and cash equivalents was -475,078,652.65, compared to -245,818,985.65 in the previous period[84] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,006,903,207.02, a slight decrease of 0.76% from ¥2,984,122,442.23 at the end of the previous year[11] - Total assets decreased by 35.28% in cash and cash equivalents to ¥871,672,211.69, as cash management limits increased[25] - The total assets of the company reached ¥2,608,033,482.25, an increase from ¥2,354,627,398.08 at the end of 2019, indicating growth in asset base[60] - The total liabilities decreased slightly to CNY 692.72 million from CNY 722.20 million, a reduction of approximately 4.1%[50] - The total liabilities amounted to ¥435,240,896.19, up from ¥228,262,154.44, reflecting increased financial obligations[60] - Total liabilities amounted to ¥722,200,453.19, with total equity at ¥2,261,921,989.04, resulting in total assets of ¥2,984,122,442.23[96] Shareholder Equity - The net assets attributable to shareholders increased by 2.34% to ¥2,298,053,716.13 from ¥2,245,540,256.32 at the end of the previous year[11] - The company's equity increased to CNY 2.31 billion, up from CNY 2.26 billion, indicating a growth of about 2.2%[50] - The company's equity attributable to shareholders increased to ¥2,172,792,586.06 from ¥2,126,365,243.64, showing a positive trend in shareholder value[60] - The company has unallocated profits of ¥897,435,316.33, contributing to total equity of ¥2,126,365,243.64[99] Government and Non-Operating Income - The company received government subsidies amounting to ¥85,447.38 during the reporting period[11] - The company reported a non-operating income of ¥4,077,534.25 from investment products during the reporting period[11] Operational Changes and Standards - The company adopted the new revenue recognition standards starting January 1, 2020, impacting financial reporting[102] - The first quarter report for 2020 was not audited, indicating preliminary financial results[103] Research and Development - Research and development expenses for Q1 2020 were ¥5,898,784.73, slightly up from ¥5,824,296.60, indicating continued investment in innovation[63] - Research and development expenses for the current period are approximately ¥4.54 million, down from ¥5.11 million, reflecting a decrease of 11%[71]